Stavudine
Sold as Aspen stavudine, Dynavir, Dynavir for, Vari-stavudine, Sonke-stavudine
1-[(2R,5S)-5-(Hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
Drag to rotate. Structure from PubChem CID 18283.
Background
Registration
- Applicants
- 5
- Registrations
- 12
- Schedule source
- Consolidated Schedules 06 July 2026
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pharmacare limited û woodmead | Aspen stavudine | 15 mg, 20 mg, 30 mg, 40 mg | 370110, 370111, 370112, 370113 | S4 | None |
| Aurogen South Africa (Pty) LtdCancelled | Dynavir | 15 mg, 20 mg, 30 mg, 40 mg | 410810, 410811, 421011, 421012 | S4 | None |
| Aurobindo Pharma (Pty) LtdCancelled | Dynavir for | 1 mg/ml | 430565 | S4 | None |
| Specpharm (Pty) LtdCancelled | Vari-stavudine | 30 mg | A390110 | S4 | None |
| Ranbaxy (SA) (Pty) LtdCancelled | Sonke-stavudine | 30, 40 | A400421, A400422 | S4 | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Aspen stavudine 15 MG EACH CAPSULE CONTAINS STAVUDINE 15,0 mg | 15 mg | 37011037/20.2.8/0110 | Registered | S4 | None |
| Aspen stavudine 20 MG EACH CAPSULE CONTAINS STAVUDINE 20,0 mg | 20 mg | 37011137/20.2.8/0111 | Registered | S4 | None |
| Aspen stavudine 30 MG EACH CAPSULE CONTAINS STAVUDINE 30,0 mg | 30 mg | 37011237/20.2.8/0112 | Registered | S4 | None |
| Aspen stavudine 40 MG EACH CAPSULE CONTAINS STAVUDINE 40,0 mg | 40 mg | 37011337/20.2.8/0113 | Registered | S4 | None |
| Dynavir capsules 15 MG EACH CAPSULE CONTAINS STAVUDINE 15,0 mg | 15 mgCapsules | 41081041/20.2.8/0810 | Cancelled | S4 | None |
| Dynavir capsules 20 MG EACH CAPSULE CONTAINS STAVUDINE 20,0 mg | 20 mgCapsules | 41081141/20.2.8/0811 | Cancelled | S4 | None |
| Dynavir capsules 30 MG EACH CAPSULE CONTAINS STAVUDINE 30,0 mg | 30 mgCapsules | 42101142/20.2.8/1011 | Cancelled | S4 | None |
| Dynavir capsules 40 MG EACH CAPSULE CONTAINS STAVUDINE 40,0 mg | 40 mgCapsules | 42101242/20.2.8/1012 | Cancelled | S4 | None |
| Dynavir powder for oral solution 1 mg/ml EACH 1,0 ml SOLUTION CONTAINS STAVUDINE 1,0 mg | 1 mg/mlPowder oral solution | 43056543/20.2.8/0565 | Cancelled | S4 | None |
| Vari-stavudine 30 MG EACH CAPSULE CONTAINS STAVUDINE 30,0 mg | 30 mg | A390110A39/20.2.8/0110 | Cancelled | S4 | None |
| Sonke-stavudine 30 EACH CAPSULE CONTAINS STAVUDINE 30,0 mg | 30 | A400421A40/20.2.8/0421 | Cancelled | S4 | None |
| Sonke-stavudine 40 EACH CAPSULE CONTAINS STAVUDINE 40,0 mg | 40 | A400422A40/20.2.8/0422 | Cancelled | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Stavudine
S4: Stavudine
Consolidated Schedules 06 July 2026, line 7974
Pharmacological class: Antiviral agents. (class 20.2.8)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.